期刊文献+

Preparation and physicochemical characterization of a solid dispersion of(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T) and polyvinylpyrrolidone 被引量:2

Preparation and physicochemical characterization of a solid dispersion of(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T) and polyvinylpyrrolidone
原文传递
导出
摘要 Ischemic brain injury is a major disease which threatens human health and safety.(3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate(VA-T), a newly discovered lead compound, is effective for the treatment of ischemic brain injury and its sequelae. But the poor solubility of VA-T leads to poor dissolution and limited clinical application. In order to improve the dissolution of VA-T, the pharmaceutical technology of solid dispersions was used in the present study. VA-T/ polyvinylpyrrolidone(PVP) solid dispersion was prepared by the solvent method. The dissolution studies were carried out and solid state characterization was evaluated by differential scanning calorimetry(DSC), infrared spectroscopy(IR), x-ray diffraction(XRD) and scanning electron microscopy(SEM). The dissolution rate of VA-T was significantly improved by solid dispersion compared to that of the pure drug and physical mixture. The results of DSC and XRD indicated that the VA-T solid dispersion was amorphous. The IR spectra showed the possible interaction between VA-T and PVP was the formulation of hydrogen bonding. The SEM analysis demonstrated that there was no VA-T crystal observed in the solid dispersions. The ideal drug-to-PVP ratio was 1 : 5. In conclusion, the solid dispersion technique can be successfully used for the improvement of the dissolution profile of VA-T. Ischemic brain injury is a major disease which threatens human health and safety. (3, 5, 6-trimethylpyrazin-2-yl) methyl 3-methoxy-4-[(3, 5, 6-trimethylpyrazin-2-yl) methoxy] benzoate (VA-T), a newly discovered lead compound, is effective for the treatment of ischemic brain injury and its sequelae. But the poor solubility of VA-T leads to poor dissolution and limited clinical application. In order to improve the dissolution of VA-T, the pharmaceutical technology of solid dispersions was used in the present study. VA-T/polyvinylpyrrolidone (PVP) solid dispersion was prepared by the solvent method. The dissolution studies were carried out and solid state characterization was evaluated by differential scanning calorimetry (DSC), infrared spectroscopy (IR), x-ray diffraction (XRD) and scanning electron microscopy (SEM). The dissolution rate of VA-T was significantly improved by solid dispersion compared to that of the pure drug and physical mixture. The results of DSC and XRD indicated that the VA-T solid dispersion was amorphous. The IR spectra showed the possible interaction between VA-T and PVP was the formulation of hydrogen bonding. The SEM analysis demonstrated that there was no VA-T crystal observed in the solid dispersions. The ideal drug-to-PVP ratio was 1 : 5. In conclusion, the solid dispersion technique can be successfully used for the improvement of the dissolution profile of VA-T.
出处 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2015年第11期861-866,共6页 中国天然药物(英文版)
基金 financially supported by National Natural Science Foundation of China(No.81173563) Ministry of National Science and Technology(China Nos.2012ZX09103201-026 2009ZX09102-142) the Innovation Team of Beijing University of Chinese Medicine(No.2011-CXTD-13)
关键词 VA-T Ischemic stroke Solid dispersions Dissolution Physicochemical characterization 药理学 药物 性质 生化 化学
  • 相关文献

参考文献19

  • 1Wang PL, Zhang HG, Chu FH, et al. Synthesis and protective effect of new Ligustrazine-Benzoic acid derivatives against CoCL-induced neurotoxicity in differentiated PC12 cells [J]. Molecules, 2013, 18(10): 13027-13042.
  • 2Uchino T, Yasuno N, Yanagihara Y, et al. Solid dispersion of spironolactone with porous silica prepared by the solvent method [J], Pharmazie, 2007, 62(8): 599-603.
  • 3Modi A, Tayade P. Enhancement of dissolution profile by solid dispersion (kneading) technique [J], AAPS Pharmscitech,2006, 7(3): E87-E92.
  • 4Al-Hamidi H. Edwards AA, Mohammad MA, et al. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations [J]. Colloids Surf B: Biointerfaces, 2010. 76(1): 170-178.
  • 5Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds [J], EurJ Pharm Sci, 2003, 18(2): 113-120.
  • 6Roy S, Mandal M, Pal C, et al. Studies on aqueous solubility of 3, 3D’-diindolylmethane derivatives using cyelodextrin inclusion complexes [J], J Mo! Struct, 2013, 1036: 1-6.
  • 7Hou P, Cao SL, Ni J, et al. In vitro and in vivo comparison of T-OA microemulsions and solid dispersions based on EPDC [J], Drug Dev hid Pharm, 2013, published online. DOI: 10.3109/ 03639045.2013.858739.
  • 8Hou P. Ni J, Cao SL, et al. Preparation and evaluation of solid dispersions of a new antitumor compound based on early-stage preparation discovery concept [J], AAPS Pharm Sci Tech, 2013, 14(2): 629-638.
  • 9Damian F, Blaton N, Naescns L, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14 [J]. EurJ Pharm Sci, 2000, 10: 311-322.
  • 10Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems [J], J Pharm Sci, 1971, 60: 1281-1302.

同被引文献6

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部